DORPHAN S.A.
Drugs for orphan and rare genetic diseases
DORPHAN S.A. is a limited company under Swiss legal jurisdiction, whose objective is the development of treatments for rare and orphan genetic diseases, in particular those severely affecting children. The company has ongoing collaborative activities with academic institutions, private service providers and pharmaceutical companies to sustain the development of treatments for rare and orphan genetic diseases.
The company is assembling a portfolio of promising drug candidates and then, leads and supervises their pre-clinical development.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
02.03.2017
Biotech startups receive the CTI startup label (startupticker.ch)
No milestones
No Jobs
No videos and documents
No Awards
DORPHAN S.A.
Drugs for orphan and rare genetic diseases
Website:
www.dorphan.com
Headquarter:
Lausanne
Foundation Date:
March 2011
Technology:
- Biotech
Sectors:
- Drug discovery